Medical University of Vienna
meduniwien.ac.atLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,094
Active
153
Phase 3
67
Total enrollment
1,838,235
Pipeline matrix
Showing 40 of 65 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Desflurane | — | — | — | — | — | 2 | |
| Sevoflurane | — | — | — | — | — | 2 | |
| Unfractionated heparin | — | — | — | — | 2 | ||
| Methotrexate | — | — | — | — | — | 1 | |
| WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline | — | — | — | — | — | 1 | |
| Cipralex | — | — | — | — | — | 1 | |
| Methohexital | — | — | — | — | — | 1 | |
| Ketofol | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | — | 1 | |
| Platelet Concentrate | — | — | — | — | — | 1 | |
| Prothrombin Complex Concentrate | — | — | — | — | — | 1 | |
| Enoxaparin Injectable Solution | — | — | — | — | — | 1 | |
| Argatroban, 1 Mg/mL Intravenous Solution | — | — | — | — | — | 1 | |
| Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions | — | — | — | — | — | 1 | |
| anti-VEGF agent | — | — | — | — | — | 1 | |
| [177Lu]Lu-PSMA I&T | — | — | — | — | — | 2 | |
| BT200 | — | — | — | — | — | 2 | |
| Polatuzumab, bendamustin und rituximab | — | — | — | — | — | 1 | |
| Bexsero | — | — | — | — | — | 1 | |
| Systemic application of simultaneous chemotherapy | — | — | — | — | — | 1 | |
| Datopotamab deruxtecan | — | — | — | — | — | 1 | |
| Thalidomide | — | — | — | — | — | 1 | |
| Celecoxib | — | — | — | — | — | 1 | |
| Fenofibric acid | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Etoposide phosphate | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Arexvy powder and suspension for | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | 5 | |||
| Psilocybin | — | — | — | — | — | 1 | |
| Risperidone 1 MG | — | — | — | — | — | 1 | |
| MRI contrast-enhancing agents | — | — | — | — | — | 1 | |
| Fluid bolus | — | — | — | — | 3 | ||
| Midazolam | — | — | — | — | 6 | ||
| Docetaxel | — | — | — | — | 3 | ||
| Dupilumab | — | — | — | — | 2 | ||
| gender affirming hormone therapy | — | — | — | — | — | 1 |
25 more active programs hidden
Next readouts
- 2021-12-31
- 2025-08-31
- 2025-10-31
- 2025-11
- 2025-12
- 2025-12
- 2025-12-31
- 2025-12-31
- 2025-12-31
- 2026-01
Top conditions
- Healthy27
- Regional Blood Flow21
- Ocular Physiology18
- Glaucoma15
- Cataract15
- Critical Illness12
- Coronary Artery Disease12
- Dry Eye Syndromes12
Frequently asked questions about Medical University of Vienna
- How many clinical trials does Medical University of Vienna have on ClinicalTrials.gov?
- Medical University of Vienna is listed as the lead sponsor on 1,094 clinical trials in ClinicalTrials.gov, 153 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Medical University of Vienna's trials are in Phase 3?
- 67 of Medical University of Vienna's trials are in Phase 3, spread across 65 active drug programs.
- What therapeutic areas does Medical University of Vienna focus on?
- Medical University of Vienna's most-studied conditions on ClinicalTrials.gov are Healthy, Regional Blood Flow, Ocular Physiology, Glaucoma, Cataract.
- When are Medical University of Vienna's next clinical trial readouts?
- Medical University of Vienna has 10 upcoming primary-completion readouts tracked here; the soonest is “Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer”, expected around 2021-12-31.